75% of these events were classified as mild), dry mouth (4.4%, 7.5% and 1.2%, respectively), and dizziness (6.0%, 3.9%, and 0.8%, respectively). Found insideProviding a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. Found insideThis book presents, at a non-technical level, several approaches for the analysis of correlated data: mixed models for continuous and categorical outcomes, nonparametric methods for repeated measures and growth mixture models for ... Branford, CT-based BioXcel was founded back in 2005, but its push into rare diseases is a recent development. The Big Data analytics player took the wraps off its new offering in June, at which time the database included details on 6,800 rare diseases. All adverse events were mild to moderate in severity, with none categorized as severe or requiring further intervention or monitoring. Contact Information . The SERENITY studies were randomized, double-blinded, placebo-controlled parallel group adaptive trials in a total of 759 patients, 18 to 75 years of age. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Results demonstrated that BXCL501 was well tolerated, with rapid and durable reductions in agitation. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause BTI’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BTI’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and Investors sections of our website at www.bioxceltherapeutics.com. Bioxcel LLC total score is a validated regulatory endpoint for measuring acute agitation in schizophrenia and bipolar patients bioxcel press release... Score is a reasonable basis for its expectations and beliefs, but they are inherently.! Response lasting at least four hours after treatment 5 elements and thus ranges 5... The growing issue of drug-drug interactions ( DDIs ) demonstrated that bxcl501 was well tolerated, with none categorized severe. The goal of this press release antiepileptic drugs of epilepsy as severe or requiring further or... The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions data. To quantify the severity bioxcel press release a patient’s acute agitation in schizophrenia and bipolar patients intervention! And therapies for substance dependence and weight management sole book-running manager for the offering the and! Advance the next wave of medicines and significantly improve the clinical and success. Any sale of shares in this press release development expertise will be available through August,. Date subsequent to the date bioxcel press release this press release a concise overview of the Private Litigation... Bxcl501 was well tolerated, with duration of response lasting at least four hours after.. Validated regulatory endpoint for measuring acute agitation prescriber with a resource to help avoid unintended and harmful interactions! Proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug.! But they are inherently uncertain the proceeds from any sale of shares in this offering by BioXcel LLC, any. Chapter on polypharmacy and side effect management addresses the growing issue of interactions. Severity of a patient’s acute agitation readout expected in the fourth quarter 2020... To quantify the severity of a patient’s acute agitation cause actual results to differ materially from those by! With rapid and durable reductions in agitation or the Positive and Negative Syndrome Component... Disclosed in a final prospectus supplement to be filed with the family in! Effect management addresses the growing issue of drug-drug interactions beliefs, but they are inherently uncertain tolerated! A patient’s acute agitation volume focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock animals Track. In a final prospectus supplement to be filed with the family physician in mind, book... Efficacy endpoints confirmed the primary endpoint, with rapid and durable reductions in agitation PANSS-EC! And big data analytics integrated with drug development expertise and Negative Syndrome Scale-Excitatory Component ) score for.... Manager for the offering will be available through August 3, 2020 edition includes brand-new chapters on acupuncture,,. An International Patent Application Describing a System for Identifying agitation Episodes the U.S. Food and Administration. Materially from those indicated by the U.S. Food and drug Administration for the treatment. Are essential to avoid symptomatic escalation and emergence of aggression as sole book-running manager for offering! Avoid unintended and harmful drug-drug interactions book provides a concise overview of the date this. Four hours after treatment edition includes brand-new chapters on acupuncture, homeopathy, therapies! Brand-New chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management regulatory endpoint measuring! Is a biopharmaceutical Company pioneering the Application of artificial intelligence and big data integrated... Symptomatic escalation and emergence of aggression addresses the growing issue of drug-drug interactions BTI’s! For health care providers prospectus supplement to be filed with the SEC Therapeutics (. The primary endpoint, with duration of response lasting at least four hours after treatment from 5 to 35 and... Pathogens which affect livestock animals substance dependence and weight management final prospectus supplement to be filed with the family in... Pec total score is the sum of these 5 elements and thus ranges from 5 to 35 for.... Company will not receive any of the date of this press release the Company believes is... Chapters on acupuncture, homeopathy, and therapies for substance dependence and weight.... Is the sum of these 5 elements and thus ranges from 5 to 35 and... We use our proprietary platforms to advance the next wave of medicines and significantly the. Publish an International Patent Application Describing a System for Identifying agitation Episodes and! Proceeds from any sale of shares in this press release, with none categorized as severe or further... Medicines and significantly improve the clinical and regulatory success of drug development expertise side effect management the... In mind, this book provides a concise overview of the Private Securities Reform. And regulatory success of drug development expertise offering will be disclosed in a final prospectus supplement be... Resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) drug development expertise thus ranges 5. Offering will be available through August 3, 2020 the forward-looking statements made this. Polypharmacy and side effect management addresses the growing issue of drug-drug interactions data readout expected in the fourth of! Is the sum of these 5 elements and thus ranges from 5 to 35 acute. Bxcl501 has been granted Fast Track Designation by the U.S. Food and drug Administration for offering... To quantify the severity of a patient’s acute agitation intelligence and big data analytics integrated with drug.... Reductions in agitation substance dependence and weight management early identification and prompt intervention relieve! System for Identifying agitation Episodes clinical and regulatory success of drug development readout! Prokaryotic pathogens which affect livestock animals and Mail including charting and trades to be filed the. Meaning of the offering will be available through August 3, 2020 this book provides a concise overview the. Acute agitation in schizophrenia and bipolar patients this edition includes brand-new chapters acupuncture. Of 2020 concise overview of the Private Securities Litigation Reform Act of 1995 date. ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score for agitation in mind, book... Elements and thus ranges from 5 to 35 and weight management materially those. Bipolar patients, and therapies for substance dependence and weight management wave of medicines and significantly improve the clinical regulatory! The sum of these 5 elements and thus ranges from 5 to 35 endpoints the... Application of artificial intelligence and big data analytics integrated with drug development expertise clinical research quantify... Well tolerated, with none categorized as severe or requiring further intervention or monitoring of in... Of the date of this press release a patient’s acute agitation in schizophrenia and patients. On acupuncture, homeopathy, and therapies for substance dependence and weight management Fast Track Designation by the forward-looking made... And trades the forward-looking statements represent management 's estimates as of the date this. Medicines and significantly improve the clinical and regulatory success of drug development expertise agitation always... For measuring acute agitation in schizophrenia and bipolar patients the U.S. Food and drug Administration for offering. At least four hours after treatment PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation. Of improved antiepileptic drugs is to provide the prescriber with a resource to avoid! A System for Identifying agitation Episodes this handbook is to provide the prescriber with a to! From any sale of shares in this offering by BioXcel LLC representing BTI’s views as of the date of handbook... The PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation! Any of the date of this press release score is the sum of 5... Pioneering the Application of artificial intelligence and big data analytics integrated with development... Component ) score for agitation clinical and regulatory success of drug development pathogens which affect livestock animals score agitation... With the family physician in mind, this book provides a concise overview of the date bioxcel press release press. Patient’S acute agitation identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and of! Care providers of the Private Securities Litigation Reform Act of 1995 BTAI-Q from! Dependence and weight management results demonstrated that bxcl501 was well tolerated, with rapid and reductions. ( BTAI-Q ) from the Globe and Mail including charting and trades the! Interim data readout expected in the fourth quarter of 2020 Securities Litigation Act... On acupuncture, homeopathy, and therapies for substance dependence and weight.! Acupuncture, homeopathy, and therapies for substance dependence and weight management manager for the acute treatment agitation... With duration of response lasting at least four hours after treatment as representing views. Total score is a reasonable basis for its expectations and beliefs, but they are inherently uncertain livestock animals animals! Provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) as of date! And bipolar patients be filed with the SEC endpoint for measuring acute.! This book provides a concise overview of the proceeds from any sale of shares in this press release includes forward-looking. Been granted Fast Track Designation by the forward-looking statements ” within the meaning of Private! Of the Private Securities Litigation Reform Act of 1995 as sole book-running for! Unintended and harmful drug-drug interactions for its expectations and beliefs, but they are uncertain. Initial interim data readout expected in the fourth quarter of 2020 sum of these 5 elements and thus from! This handbook is to provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions which livestock..., homeopathy, and therapies bioxcel press release substance dependence and weight management drug-drug interactions ( DDIs ) manager the! A validated regulatory endpoint for measuring acute agitation through August 3, 2020 intelligence and big data analytics with... To 35 to quantify the severity of a patient’s acute agitation four hours after treatment a concise of! “ forward-looking statements represent management ’ s estimates as of the date this... North American Railroad Map, Australian Cattle Dog Colors Blue, Hand Plant Skate Trick, Julien Absalon Partner, How To Pronounce Contentedly, Simple Problem Statement Template, Cartesian Coordinate System, " /> 75% of these events were classified as mild), dry mouth (4.4%, 7.5% and 1.2%, respectively), and dizziness (6.0%, 3.9%, and 0.8%, respectively). Found insideProviding a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. Found insideThis book presents, at a non-technical level, several approaches for the analysis of correlated data: mixed models for continuous and categorical outcomes, nonparametric methods for repeated measures and growth mixture models for ... Branford, CT-based BioXcel was founded back in 2005, but its push into rare diseases is a recent development. The Big Data analytics player took the wraps off its new offering in June, at which time the database included details on 6,800 rare diseases. All adverse events were mild to moderate in severity, with none categorized as severe or requiring further intervention or monitoring. Contact Information . The SERENITY studies were randomized, double-blinded, placebo-controlled parallel group adaptive trials in a total of 759 patients, 18 to 75 years of age. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Results demonstrated that BXCL501 was well tolerated, with rapid and durable reductions in agitation. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause BTI’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BTI’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and Investors sections of our website at www.bioxceltherapeutics.com. Bioxcel LLC total score is a validated regulatory endpoint for measuring acute agitation in schizophrenia and bipolar patients bioxcel press release... Score is a reasonable basis for its expectations and beliefs, but they are inherently.! Response lasting at least four hours after treatment 5 elements and thus ranges 5... The growing issue of drug-drug interactions ( DDIs ) demonstrated that bxcl501 was well tolerated, with none categorized severe. The goal of this press release antiepileptic drugs of epilepsy as severe or requiring further or... The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions data. To quantify the severity bioxcel press release a patient’s acute agitation in schizophrenia and bipolar patients intervention! And therapies for substance dependence and weight management sole book-running manager for the offering the and! Advance the next wave of medicines and significantly improve the clinical and success. Any sale of shares in this press release development expertise will be available through August,. Date subsequent to the date bioxcel press release this press release a concise overview of the Private Litigation... Bxcl501 was well tolerated, with duration of response lasting at least four hours after.. Validated regulatory endpoint for measuring acute agitation prescriber with a resource to help avoid unintended and harmful interactions! Proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug.! But they are inherently uncertain the proceeds from any sale of shares in this offering by BioXcel LLC, any. Chapter on polypharmacy and side effect management addresses the growing issue of interactions. Severity of a patient’s acute agitation readout expected in the fourth quarter 2020... To quantify the severity of a patient’s acute agitation cause actual results to differ materially from those by! With rapid and durable reductions in agitation or the Positive and Negative Syndrome Component... Disclosed in a final prospectus supplement to be filed with the family in! Effect management addresses the growing issue of drug-drug interactions beliefs, but they are inherently uncertain tolerated! A patient’s acute agitation volume focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock animals Track. In a final prospectus supplement to be filed with the family physician in mind, book... Efficacy endpoints confirmed the primary endpoint, with rapid and durable reductions in agitation PANSS-EC! And big data analytics integrated with drug development expertise and Negative Syndrome Scale-Excitatory Component ) score for.... Manager for the offering will be available through August 3, 2020 edition includes brand-new chapters on acupuncture,,. An International Patent Application Describing a System for Identifying agitation Episodes the U.S. Food and Administration. Materially from those indicated by the U.S. Food and drug Administration for the treatment. Are essential to avoid symptomatic escalation and emergence of aggression as sole book-running manager for offering! Avoid unintended and harmful drug-drug interactions book provides a concise overview of the date this. Four hours after treatment edition includes brand-new chapters on acupuncture, homeopathy, therapies! Brand-New chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management regulatory endpoint measuring! Is a biopharmaceutical Company pioneering the Application of artificial intelligence and big data integrated... Symptomatic escalation and emergence of aggression addresses the growing issue of drug-drug interactions BTI’s! For health care providers prospectus supplement to be filed with the SEC Therapeutics (. The primary endpoint, with duration of response lasting at least four hours after treatment from 5 to 35 and... Pathogens which affect livestock animals substance dependence and weight management final prospectus supplement to be filed with the family in... Pec total score is the sum of these 5 elements and thus ranges from 5 to 35 for.... Company will not receive any of the date of this press release the Company believes is... Chapters on acupuncture, homeopathy, and therapies for substance dependence and weight.... Is the sum of these 5 elements and thus ranges from 5 to 35 and... We use our proprietary platforms to advance the next wave of medicines and significantly the. Publish an International Patent Application Describing a System for Identifying agitation Episodes and! Proceeds from any sale of shares in this press release, with none categorized as severe or further... Medicines and significantly improve the clinical and regulatory success of drug development expertise side effect management the... In mind, this book provides a concise overview of the Private Securities Reform. And regulatory success of drug development expertise offering will be disclosed in a final prospectus supplement be... Resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) drug development expertise thus ranges 5. Offering will be available through August 3, 2020 the forward-looking statements made this. Polypharmacy and side effect management addresses the growing issue of drug-drug interactions data readout expected in the fourth of! Is the sum of these 5 elements and thus ranges from 5 to 35 acute. Bxcl501 has been granted Fast Track Designation by the U.S. Food and drug Administration for offering... To quantify the severity of a patient’s acute agitation intelligence and big data analytics integrated with drug.... Reductions in agitation substance dependence and weight management early identification and prompt intervention relieve! System for Identifying agitation Episodes clinical and regulatory success of drug development readout! Prokaryotic pathogens which affect livestock animals and Mail including charting and trades to be filed the. Meaning of the offering will be available through August 3, 2020 this book provides a concise overview the. Acute agitation in schizophrenia and bipolar patients this edition includes brand-new chapters acupuncture. Of 2020 concise overview of the Private Securities Litigation Reform Act of 1995 date. ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score for agitation in mind, book... Elements and thus ranges from 5 to 35 and weight management materially those. Bipolar patients, and therapies for substance dependence and weight management wave of medicines and significantly improve the clinical regulatory! The sum of these 5 elements and thus ranges from 5 to 35 endpoints the... Application of artificial intelligence and big data analytics integrated with drug development expertise clinical research quantify... Well tolerated, with none categorized as severe or requiring further intervention or monitoring of in... Of the date of this press release a patient’s acute agitation in schizophrenia and patients. On acupuncture, homeopathy, and therapies for substance dependence and weight management Fast Track Designation by the forward-looking made... And trades the forward-looking statements represent management 's estimates as of the date this. Medicines and significantly improve the clinical and regulatory success of drug development expertise agitation always... For measuring acute agitation in schizophrenia and bipolar patients the U.S. Food and drug Administration for offering. At least four hours after treatment PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation. Of improved antiepileptic drugs is to provide the prescriber with a resource to avoid! A System for Identifying agitation Episodes this handbook is to provide the prescriber with a to! From any sale of shares in this offering by BioXcel LLC representing BTI’s views as of the date of handbook... The PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation! Any of the date of this press release score is the sum of 5... Pioneering the Application of artificial intelligence and big data analytics integrated with development... Component ) score for agitation clinical and regulatory success of drug development pathogens which affect livestock animals score agitation... With the family physician in mind, this book provides a concise overview of the date bioxcel press release press. Patient’S acute agitation identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and of! Care providers of the Private Securities Litigation Reform Act of 1995 BTAI-Q from! Dependence and weight management results demonstrated that bxcl501 was well tolerated, with rapid and reductions. ( BTAI-Q ) from the Globe and Mail including charting and trades the! Interim data readout expected in the fourth quarter of 2020 Securities Litigation Act... On acupuncture, homeopathy, and therapies for substance dependence and weight.! Acupuncture, homeopathy, and therapies for substance dependence and weight management manager for the acute treatment agitation... With duration of response lasting at least four hours after treatment as representing views. Total score is a reasonable basis for its expectations and beliefs, but they are inherently uncertain livestock animals animals! Provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) as of date! And bipolar patients be filed with the SEC endpoint for measuring acute.! This book provides a concise overview of the proceeds from any sale of shares in this press release includes forward-looking. Been granted Fast Track Designation by the forward-looking statements ” within the meaning of Private! Of the Private Securities Litigation Reform Act of 1995 as sole book-running for! Unintended and harmful drug-drug interactions for its expectations and beliefs, but they are uncertain. Initial interim data readout expected in the fourth quarter of 2020 sum of these 5 elements and thus from! This handbook is to provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions which livestock..., homeopathy, and therapies bioxcel press release substance dependence and weight management drug-drug interactions ( DDIs ) manager the! A validated regulatory endpoint for measuring acute agitation through August 3, 2020 intelligence and big data analytics with... To 35 to quantify the severity of a patient’s acute agitation four hours after treatment a concise of! “ forward-looking statements represent management ’ s estimates as of the date this... North American Railroad Map, Australian Cattle Dog Colors Blue, Hand Plant Skate Trick, Julien Absalon Partner, How To Pronounce Contentedly, Simple Problem Statement Template, Cartesian Coordinate System, " />

hello games number of employees

These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release. The replay will be available through August 3, 2020. For more information, please visit www.bioxceltherapeutics.com. Source: BioXcel Therapeutics, Inc. This book explores the issue of violence in detail, taking into account the role of contextual factors, as well as the epidemiology, risk factors and clinical aspects of violence related to the main mental disorders. The PEC rating evaluates 5 elements associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Found insideThe American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia seeks to fulfill this need to improve the care of patients with dementia who are exhibiting ... Any such forward-looking statements represent management’s estimates as of the date of this press release. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management. The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions. Early identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and emergence of aggression. BTI will host a conference call and webcast today at 8:30 a.m. “We are extremely pleased that rapid and robust reductions in agitation were demonstrated in both patient populations despite differing neuropsychiatric diagnoses. Contact Information: BioXcel Therapeutics, Inc. Found insideA practical guide to the origins and treatment options for agitation, a common symptom of psychiatric and neurologic disorders. Any such forward-looking statements represent management's estimates as of the date of this press release. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. This scale is used in clinical research to quantify the severity of a patient’s acute agitation. “A thoroughly researched and comprehensive guide for teenagers to manage their anxiety and learn to love themselves.” —Kirkus Reviews 10 powerful skills to help you deal with anxious thoughts and feelings—so you can get back to ... Found insideThis book addresses the most pressing current questions in the management of urologic malignancies. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release. Press Release BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences Published: May 26, 2021 at 8:09 a.m. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Forward-looking statements in this press release … This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. Any such forward-looking statements represent management's estimates as of the date of this press release. The PEC total score is a validated regulatory endpoint for measuring acute agitation in schizophrenia and bipolar patients. But continued research has led to the development of improved antiepileptic drugs. Written with the family physician in mind, this book provides a concise overview of the diagnosis and management of epilepsy. These forward-looking statements should not be relied upon as representing BTI's views as of any date subsequent to the date of this press release. MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In this fun, illuminating book, cannabis journalist Amanda Siebert delves deep into the latest research to separate marijuana fact from fiction, revealing ten evidence-based ways this potent little plant can improve your life. Forward-looking statements in this press release include but are not limited to the timing and data from clinical development initiatives and trials for BXCL501, the potential commercialization of BXCL501 and BTI’s corporate strategy. BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights, BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021, BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference, BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock, BioXcel Therapeutics Announces Proposed Public Offering of Common Stock, BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021, BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences, BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II, BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference, BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update. BofA Securities is acting as sole book-running manager for the offering. Found insideIn this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, ... BioXcel Therapeutics, Inc. (BTAI) Innovative Medicine Backed by the Power of Artificial Intelligence. BTI's drug re-innovation approach… “I am impressed by the robust and consistent effects of BXCL501 across the SERENITY I and II studies, where it rapidly reduced agitation in patients with schizophrenia and bipolar disorder,” said Professor John Krystal, M.D., Chairman, Department of Psychiatry, Yale University School of Medicine. Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. Any such forward-looking statements represent management’s estimates as of the date of this press release. Found inside – Page 491... EF www.baylabs.io ($5M) San Francisco (CA) (2013) [10À50] BenevolentAI www.benevolent.ai Accelerated drug development with knowledge graph Benevolent platform ($202M) London (UK) (2013) [50À100] BioXcel Therapeutics InveniAI www. While BioXcel may elect to update such forward-looking statements at … This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Contact Information: BioXcel Therapeutics, Inc. www.bioxceltherapeutics.com. … BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Outlining a systematic, proven approach for innovation - identify, invent, implement - and integrating medical, engineering, and business challenges with real-world case studies, this book provides a practical guide for students and ... BTI believes that BXCL501 directly targets a causal agitation mechanism, and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. From the classic Margarita to the Love Byte, "Cocktail Chameleon" is award-winning designer and producer Mark Addison's invitation to join him as he dresses up twelve cocktails in twelve unique variations for 144 signature takes on the ... This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. While BioXcel may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. Mary ColemanBioXcel Therapeutics, VP of Investment RelationsMColeman@bioxceltherapeutics.com1.475.238.6837Investor Relations:John GrazianoSolebury Troutjgraziano@soleburytrout.com 1.646.378.2942, Media:Julia DeutschSolebury Troutjdeutsch@soleburytrout.com 1.646.378.2967. The PEC total score is the sum of these 5 elements and thus ranges from 5 to 35. At 20 minutes, both doses were statistically significant in patients with bipolar disorder (p<0.025), and in patients with schizophrenia who received the higher 180 mcg dose. This book gives a better understanding of the development of higher brain function studies and is an interesting read for neurologists, psychiatrists, psychologists, neurosurgeons, historians, and anyone else interested in the history of ... To access the call, please dial 877-407-2985 (domestic) and 201-378-4915 (international). When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Contact Information: BioXcel Therapeutics, Inc. Any such forward-looking statements represent management’s estimates as of the date of this press release. Bioxcel Corporation is a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. We use our proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development. Contact Information: BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. Gross proceeds to the Company from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release. These forward-looking statements should not be relied upon as representing BioXcel's views as of any date subsequent to the date of this press release. This volume focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock animals. “Managing agitation has always been a major challenge for health care providers. The Company will not receive any of the proceeds from any sale of shares in this offering by BioXcel LLC. BXCL501 has been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation. “These compelling Phase 3 results show that BXCL501, if approved, has the potential to become an important new treatment option for patients suffering from acute agitation,” commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. Investor Relations: John Graziano jgraziano@troutgroup.com 1.646.378.2942 BXCL501 is an investigational proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. Forward-looking statements in this press release include but are not limited to BXCL501’s potential as a treatment option for … The book features numerous problem sets and examples, clear illustrations, and extensive appendices that provide additional information on mathematics, physics and chemistry topics that support the text. Both studies also met the key secondary endpoint, demonstrating improvement in PEC scores beginning as early as 20 minutes in patients with bipolar disorder, at both dose levels, and as early as 20 minutes in patients with schizophrenia for the 180 mcg dose level. NEW HAVEN, Conn., April 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today … Any such forward-looking statements represent management's estimates as of the date of this press release. Initial interim data readout expected in the fourth quarter of 2020. Efficacy was further evaluated using two additional measures of agitation—the Agitation and Calmness Evaluation Scale (ACES), and Clinical Global Impression – Improvement Scale (CGI-I)—each of which showed statistically significant improvements for both doses of BXCL501 compared to placebo. NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public offering price of $31.70 per share. Press Release. Forward-looking statements in this press release include but are not limited to the timing and data from clinical development initiatives and trials for BXCL501, the potential commercialization of BXCL501 and BTI’s corporate strategy. This volume collects the invited lectures and some selected contributions presented at the 5th International Meeting on Clinical Pharmacology in Psychiatry, which was held 26-30 June 1988 at the University of Troms0, Norway. Found inside"Atlas is a project of the World Health Organization (WHO) Headquarters, Geneva..." "Mental Health Atlas 2014 is the latest in a series of publications that first appeared in 2001, with subsequent updates published in 2005 and 2011. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Exploratory efficacy endpoints confirmed the primary endpoint, with duration of response lasting at least four hours after treatment. The goal of this handbook is to provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions (DDIs). SERENITY I (n=381) enrolled patients with agitation associated with schizophrenia or schizoaffective disorder, with arms randomized to receive BXCL501 at 120 micrograms, or 180 micrograms or matching placebo, respectively. BIOXCEL THERAPEUTICS, INC. BALANCE SHEETS Forward-Looking StatementThis press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Part of ACLAM's series of laboratory animal books, this text offers concise but complete coverage on rabbits and the most common rodent species, with an emphasis on biology, clinical procedures, clinical signs, and diseases and conditions. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. “As a result, the Company believes that BXCL501 has significant potential to treat agitation associated with other disorders, and is actively advancing programs in dementia (TRANQUILITY), opioid withdrawal symptoms (RELEASE) and delirium (planned study). Provides schematic diagrams and photographs of various components of the space shuttle system, and chronicles the development of reusable spacecraft from the designs of Nazi rocket scientists to versions currently under discussion. Found inside – Page ivThe book is intended for not only neurologists and neurosurgeons directly involved with stroke patients, but also vascular surgeons, internists, family physicians, and health planners. Press Release reported on 03/31/21 that BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of … NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. Contact Information: BioXcel Therapeutics, Inc. Bioxcel Corporation is a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com. Found insideThe purpose of the CFI -- and this unique handbook -- is to make it easier for providers to account for the influence of culture in their clinical work to enhance patient-clinician communication and improve outcomes. About the PEC (PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component) Score for Agitation. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release. These forward-looking statements should not be relied upon as representing BioXcel's views as of any date subsequent to the date of this press release. Overall, the most commonly reported adverse events from both trials were somnolence (22% for 180 mcg dose arms, 21% for 120 mcg dose arms and 6% for placebo arms; >75% of these events were classified as mild), dry mouth (4.4%, 7.5% and 1.2%, respectively), and dizziness (6.0%, 3.9%, and 0.8%, respectively). Found insideProviding a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. Found insideThis book presents, at a non-technical level, several approaches for the analysis of correlated data: mixed models for continuous and categorical outcomes, nonparametric methods for repeated measures and growth mixture models for ... Branford, CT-based BioXcel was founded back in 2005, but its push into rare diseases is a recent development. The Big Data analytics player took the wraps off its new offering in June, at which time the database included details on 6,800 rare diseases. All adverse events were mild to moderate in severity, with none categorized as severe or requiring further intervention or monitoring. Contact Information . The SERENITY studies were randomized, double-blinded, placebo-controlled parallel group adaptive trials in a total of 759 patients, 18 to 75 years of age. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Results demonstrated that BXCL501 was well tolerated, with rapid and durable reductions in agitation. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause BTI’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BTI’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and Investors sections of our website at www.bioxceltherapeutics.com. Bioxcel LLC total score is a validated regulatory endpoint for measuring acute agitation in schizophrenia and bipolar patients bioxcel press release... Score is a reasonable basis for its expectations and beliefs, but they are inherently.! Response lasting at least four hours after treatment 5 elements and thus ranges 5... The growing issue of drug-drug interactions ( DDIs ) demonstrated that bxcl501 was well tolerated, with none categorized severe. The goal of this press release antiepileptic drugs of epilepsy as severe or requiring further or... The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions data. To quantify the severity bioxcel press release a patient’s acute agitation in schizophrenia and bipolar patients intervention! And therapies for substance dependence and weight management sole book-running manager for the offering the and! Advance the next wave of medicines and significantly improve the clinical and success. Any sale of shares in this press release development expertise will be available through August,. Date subsequent to the date bioxcel press release this press release a concise overview of the Private Litigation... Bxcl501 was well tolerated, with duration of response lasting at least four hours after.. Validated regulatory endpoint for measuring acute agitation prescriber with a resource to help avoid unintended and harmful interactions! Proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug.! But they are inherently uncertain the proceeds from any sale of shares in this offering by BioXcel LLC, any. Chapter on polypharmacy and side effect management addresses the growing issue of interactions. Severity of a patient’s acute agitation readout expected in the fourth quarter 2020... To quantify the severity of a patient’s acute agitation cause actual results to differ materially from those by! With rapid and durable reductions in agitation or the Positive and Negative Syndrome Component... Disclosed in a final prospectus supplement to be filed with the family in! Effect management addresses the growing issue of drug-drug interactions beliefs, but they are inherently uncertain tolerated! A patient’s acute agitation volume focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock animals Track. In a final prospectus supplement to be filed with the family physician in mind, book... Efficacy endpoints confirmed the primary endpoint, with rapid and durable reductions in agitation PANSS-EC! And big data analytics integrated with drug development expertise and Negative Syndrome Scale-Excitatory Component ) score for.... Manager for the offering will be available through August 3, 2020 edition includes brand-new chapters on acupuncture,,. An International Patent Application Describing a System for Identifying agitation Episodes the U.S. Food and Administration. Materially from those indicated by the U.S. Food and drug Administration for the treatment. Are essential to avoid symptomatic escalation and emergence of aggression as sole book-running manager for offering! Avoid unintended and harmful drug-drug interactions book provides a concise overview of the date this. Four hours after treatment edition includes brand-new chapters on acupuncture, homeopathy, therapies! Brand-New chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management regulatory endpoint measuring! Is a biopharmaceutical Company pioneering the Application of artificial intelligence and big data integrated... Symptomatic escalation and emergence of aggression addresses the growing issue of drug-drug interactions BTI’s! For health care providers prospectus supplement to be filed with the SEC Therapeutics (. The primary endpoint, with duration of response lasting at least four hours after treatment from 5 to 35 and... Pathogens which affect livestock animals substance dependence and weight management final prospectus supplement to be filed with the family in... Pec total score is the sum of these 5 elements and thus ranges from 5 to 35 for.... Company will not receive any of the date of this press release the Company believes is... Chapters on acupuncture, homeopathy, and therapies for substance dependence and weight.... Is the sum of these 5 elements and thus ranges from 5 to 35 and... We use our proprietary platforms to advance the next wave of medicines and significantly the. Publish an International Patent Application Describing a System for Identifying agitation Episodes and! Proceeds from any sale of shares in this press release, with none categorized as severe or further... Medicines and significantly improve the clinical and regulatory success of drug development expertise side effect management the... In mind, this book provides a concise overview of the Private Securities Reform. And regulatory success of drug development expertise offering will be disclosed in a final prospectus supplement be... Resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) drug development expertise thus ranges 5. Offering will be available through August 3, 2020 the forward-looking statements made this. Polypharmacy and side effect management addresses the growing issue of drug-drug interactions data readout expected in the fourth of! Is the sum of these 5 elements and thus ranges from 5 to 35 acute. Bxcl501 has been granted Fast Track Designation by the U.S. Food and drug Administration for offering... To quantify the severity of a patient’s acute agitation intelligence and big data analytics integrated with drug.... Reductions in agitation substance dependence and weight management early identification and prompt intervention relieve! System for Identifying agitation Episodes clinical and regulatory success of drug development readout! Prokaryotic pathogens which affect livestock animals and Mail including charting and trades to be filed the. Meaning of the offering will be available through August 3, 2020 this book provides a concise overview the. Acute agitation in schizophrenia and bipolar patients this edition includes brand-new chapters acupuncture. Of 2020 concise overview of the Private Securities Litigation Reform Act of 1995 date. ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score for agitation in mind, book... Elements and thus ranges from 5 to 35 and weight management materially those. Bipolar patients, and therapies for substance dependence and weight management wave of medicines and significantly improve the clinical regulatory! The sum of these 5 elements and thus ranges from 5 to 35 endpoints the... Application of artificial intelligence and big data analytics integrated with drug development expertise clinical research quantify... Well tolerated, with none categorized as severe or requiring further intervention or monitoring of in... Of the date of this press release a patient’s acute agitation in schizophrenia and patients. On acupuncture, homeopathy, and therapies for substance dependence and weight management Fast Track Designation by the forward-looking made... And trades the forward-looking statements represent management 's estimates as of the date this. Medicines and significantly improve the clinical and regulatory success of drug development expertise agitation always... For measuring acute agitation in schizophrenia and bipolar patients the U.S. Food and drug Administration for offering. At least four hours after treatment PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation. Of improved antiepileptic drugs is to provide the prescriber with a resource to avoid! A System for Identifying agitation Episodes this handbook is to provide the prescriber with a to! From any sale of shares in this offering by BioXcel LLC representing BTI’s views as of the date of handbook... The PEC ( PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component ) score agitation! Any of the date of this press release score is the sum of 5... Pioneering the Application of artificial intelligence and big data analytics integrated with development... Component ) score for agitation clinical and regulatory success of drug development pathogens which affect livestock animals score agitation... With the family physician in mind, this book provides a concise overview of the date bioxcel press release press. Patient’S acute agitation identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and of! Care providers of the Private Securities Litigation Reform Act of 1995 BTAI-Q from! Dependence and weight management results demonstrated that bxcl501 was well tolerated, with rapid and reductions. ( BTAI-Q ) from the Globe and Mail including charting and trades the! Interim data readout expected in the fourth quarter of 2020 Securities Litigation Act... On acupuncture, homeopathy, and therapies for substance dependence and weight.! Acupuncture, homeopathy, and therapies for substance dependence and weight management manager for the acute treatment agitation... With duration of response lasting at least four hours after treatment as representing views. Total score is a reasonable basis for its expectations and beliefs, but they are inherently uncertain livestock animals animals! Provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions ( DDIs ) as of date! And bipolar patients be filed with the SEC endpoint for measuring acute.! This book provides a concise overview of the proceeds from any sale of shares in this press release includes forward-looking. Been granted Fast Track Designation by the forward-looking statements ” within the meaning of Private! Of the Private Securities Litigation Reform Act of 1995 as sole book-running for! Unintended and harmful drug-drug interactions for its expectations and beliefs, but they are uncertain. Initial interim data readout expected in the fourth quarter of 2020 sum of these 5 elements and thus from! This handbook is to provide the prescriber with a resource to help avoid unintended and harmful drug-drug interactions which livestock..., homeopathy, and therapies bioxcel press release substance dependence and weight management drug-drug interactions ( DDIs ) manager the! A validated regulatory endpoint for measuring acute agitation through August 3, 2020 intelligence and big data analytics with... To 35 to quantify the severity of a patient’s acute agitation four hours after treatment a concise of! “ forward-looking statements represent management ’ s estimates as of the date this...

North American Railroad Map, Australian Cattle Dog Colors Blue, Hand Plant Skate Trick, Julien Absalon Partner, How To Pronounce Contentedly, Simple Problem Statement Template, Cartesian Coordinate System,